Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 dose-escalation trial evaluating WT1-specific donor-derived T cells after T-cell–depleted allogeneic stem cell transplantation in re…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: REST - Replacing Steroids in the Transplant Ineligble [Phase 2]
A Phase 2 trial update on REST (Replacing Steroids in the Transplant Ineligible) for multiple myeloma has completed.
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients [Phase 2]
Phase 2 clinical trial evaluating low-dose teclistamab in newly diagnosed multiple myeloma; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study [Phase 2, Phase 3]
The REMNANT study is a phase 2/3 clinical trial for multiple myeloma conducted at Oslo University Hospital, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) [Phase 2]
Phase 2 NCI MATCH subprotocol V is evaluating sunitinib for cancers with cKIT genetic alterations, including advanced and refractory lymphom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications [Phase 1, Phase 2]
A Phase 1/2 clinical trial of KPT-8602 (eltanexor) in participants with relapsed/refractory cancer indications completed, evaluating safety,…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma [Phase 2]
Phase 2 trial update on Teclistamab-Daratumumab and Talquetamab-Daratumumab combinations in newly diagnosed high-risk multiple myeloma; the …
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating a conditioning regimen with panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell tra…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma [Phase 3]
This Phase 3 clinical trial compares belantamab mafodotin plus pomalidomide and dexamethasone against bortezomib plus pomalidomide and dexam…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial evaluates PF-06863135 as a single agent and in combination with immunomodulatory agents in relapsed/refractory multiple myel…
-
CLINICAL_TRIALS research · 2025-03-18Clinical Trial Update: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients [Phase 2]
Phase 2 clinical trial evaluating selinexor with alternating bortezomib or lenalidomide plus dexamethasone in newly diagnosed multiple myelo…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: KPD Consolidation After ASCT in NDMM Patients [Phase 2, Phase 3]
This clinical trial update describes a Phase 2/Phase 3 study evaluating consolidation with the KPD regimen after autologous stem cell transp…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) [NA]
The PHANTASTIC trial evaluating plerixafor-assisted, chemotherapy-free autologous stem cell transplantation for cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: NXC-201 (formerly HBI0101) Multiple Myeloma [Phase 1]
A Phase 1 trial of NXC-201 (formerly HBI0101) for multiple myeloma is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
A real-world study in patients with multiple myeloma on treatment to map antithrombotic regimens.
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Role of Uromodulin in Management of Multiple Myloma [NA]
This entry reports a clinical trial from Assiut University investigating the role of uromodulin in the management of multiple myeloma; the s…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
A completed Canadian real-world study examining the burden of multiple myeloma on patients and the subjective burden and quality of life for…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
This clinical trial update shows recruiting status for regimens including isatuximab to treat relapsed/refractory multiple myeloma with 1q21…
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: Ixazomib Rollover Study [Phase 2]
A Phase 2 Ixazomib rollover study has completed, with results posted on 2025-03-12. The study encompassed multiple myeloma, lymphoma, and am…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: Study on the Clinical Efficacy of Teclistamab
This clinical trial update notes that Teclistamab is currently recruiting to study its clinical efficacy in multiple myeloma and other hemat…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma [Phase 1, Phase 2]
Results from a Phase 1/2 trial of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone for relapsed and refra…
-
FDA approval · 2025-03-03FDA Approved: LENALIDOMIDE — Original Application (BIOCON PHARMA INC.,)
FDA approved Biocon Pharma Inc.'s lenalidomide as an original ANDA, enabling a generic version of the cancer drug. Indications include multi…
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM [Phase 1, Phase 2]
Results from a sub-study of belantamab mafodotin as monotherapy and in combination with dostarlimab in relapsed/refractory multiple myeloma …
-
CLINICAL_TRIALS withdrawal · 2025-03-03Clinical Trial Update: Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM [Phase 2]
A Phase 2 trial evaluating siltuximab to prevent cytokine release syndrome in patients with relapsed/refractory multiple myeloma treated wit…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: Blood Samples to Identify Biomarkers of Busulfan
A terminated clinical trial at Fred Hutchinson Cancer Center investigated using blood samples to identify biomarkers of busulfan exposure. T…